Nemaura Commences Pilot Program of Miboko with the NHS in the United Kingdom
November 29 2022 - 8:00AM
Nemaura Medical, Inc. (Nasdaq: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle and weight reduction programs,
announces that it has commenced patient studies of its proprietary
metabolic health program, Miboko, with the National Health Service
(NHS) in the United Kingdom.
Miboko, is the first metabolic tracking program
to integrate a non-invasive glucose sensor with a lifestyle app
that includes recording of food and drink, educational content, and
an analytics platform. The program gives the user a metabolic score
based on diet, exercise, and the user’s individual glucose response
to their food intake. Users are given personalized recommendations
to help them reduce weight, avoid serious health issues, such as
heart disease and diabetes, and enjoy a better quality of life.
The partnership with the UK’s NHS is through
medical centers that partner with the NHS National Institute for
Health and Care Research (NIHR) to gather information that helps
change and save lives.
Miboko is expected to be available without
prescription and is recommended for use by those wishing to lose
weight. The program will be offered to employers and insurers, as
well as direct to consumers. In the U.S. alone, the program will be
relevant to over 80 million people with prediabetes as well as to
people with obesity. Significantly, Miboko will also be used by
people who wish to embark on a diet program, of which a significant
number will have tried alternative diet plans. Miboko complements
the BEATdiabetes program that is being commercialized for people
with type 2 diabetes in the U.S. through strategic alliances, such
as the one the Company announced previously with Eversana.
Dr. Faz Chowdhury, Nemaura Medical’s Chief
Executive Officer, stated, “Use of glucose monitoring is becoming
more widespread, not just in people with diabetes, but also with
those who wish to use personalized data to aid in weight loss.
Studies have shown that glucose response to diet and lifestyle
habits can have a profound behavioral impact in helping people to
modify their diet and exercise regimes. We are very excited, both
with the response that we have had from participants and also the
weight loss results that are being reported.”
About Nemaura Medical,
Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising noninvasive wearable
diagnostic devices. The company is currently also commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, as a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and prediabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence under a digital healthcare subscription
service that has been launched in the U.S. as a general wellness
product as part of its BEAT® diabetes program that is currently
undergoing pilot studies.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit
www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura Medical’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura Medical and its partners’ ability to develop, market and
sell proBEAT™, the availability of substantial additional equity or
debt capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The U.S.
Food and Drug Administration (the “FDA”) reserves the right to
re-evaluate its decision that proBEAT™ qualifies as a general
wellness product should it become aware of any issues such as skin
irritation or other adverse events from the device, as well as any
misuse impacting patient safety, and any other reason as the FDA
may see fit at its discretion to determine the product does not fit
the definition of a general wellness product. These and other risks
and uncertainties are identified and described in more detail in
Nemaura Medical’s filings with the United States Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the most recently completed fiscal year,
its Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura Medical undertakes no obligation to publicly update or
revise any forward-looking statements.
Contact:
InvestorsBret ShapiroCORE IR561-479-8566brets@coreir.com
MediaJules AbrahamCORE IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Jul 2023 to Jul 2024